SS-31 (elamipretide): an elegant mitochondrial mechanism meets a hard clinical record

SS-31 is one of the most mechanistically elegant molecules in the mitochondrial-medicine field, and one of the most sobering case studies in how far an elegant mechanism can be from a proven drug. Known clinically as elamipretide — and previously as MTP-131 or Bendavia, developed by Stealth BioTherapeutics — it is a small mitochondria-targeting tetrapeptide that concentrates on the inner mitochondrial membrane and binds cardiolipin, the signature lipid of that membrane.^[1] The theory is beautiful. The human trial record is mixed, mostly disappointing, and — as of late 2025 — finally holds one narrow, hard-won approval. Here is the honest state of it.

The cardiolipin mechanism — why the theory is so compelling

Mitochondria make cellular energy at the inner membrane, which is folded into dense pleats called cristae. The efficiency of the electron-transport chain depends on those pleats staying tightly organized, and their organization depends heavily on cardiolipin, a unique four-tailed phospholipid found almost exclusively in the inner mitochondrial membrane. SS-31 carries an alternating aromatic-cationic structure that lets it cross membranes and accumulate inside mitochondria, where it associates selectively with cardiolipin. By binding cardiolipin, it is thought to stabilize cristae curvature, protect the lipid from peroxidation, and keep the respiratory supercomplexes properly assembled — improving electron flow and reducing the electron leakage that produces reactive oxygen species.^[1] In aged and injured tissue, preclinical work shows it can restore mitochondrial structure and function rather than merely mopping up free radicals.^[1]

That places SS-31 in a broader story of trying to repair mitochondria rather than just supply them. The mitochondrial-derived peptides — see our reviews of MOTS-c and humanin — approach the same organelle from the signaling side, while NAD+ precursors like NR and NMN aim at the electron-carrier supply. SS-31 is different in that it targets a structural lipid directly. The mechanism is arguably the most concrete of the group. What separates a good mechanism from a good drug, though, is what happens in randomized trials — and that is where the story gets harder.

Primary mitochondrial myopathy: the largest trial missed

The most important efficacy test was MMPOWER-3, a Phase 3, randomized, double-blind, placebo-controlled trial in adults with genetically confirmed primary mitochondrial myopathy. It enrolled 218 participants, randomized to 40 mg/day subcutaneous elamipretide or placebo for 24 weeks, with co-primary endpoints of change in the 6-minute walk test distance and total fatigue on a disease-specific symptom scale.^[2] The result was negative: the trial did not meet either primary endpoint, showing no significant benefit over placebo across the overall population.^[2] A pre-specified subgroup with nuclear-DNA mutations walked somewhat farther, which the authors framed as hypothesis-generating rather than conclusive.^[2] This came after an earlier Phase 1/2 dose-escalation study had reported a short-term signal on walk distance that, in hindsight, did not replicate in the pivotal trial.^[3] For the largest and best-powered indication SS-31 was tested in, the honest summary is: it failed.

Barth syndrome: a missed crossover, a promising extension, and an approval

Barth syndrome is an ultra-rare, X-linked genetic disorder — roughly one in a million male births — caused by mutations in the TAZ gene that disrupt cardiolipin remodeling, producing cardiomyopathy, skeletal-muscle weakness and neutropenia. Because the defect is a cardiolipin defect, a cardiolipin-binding peptide is a mechanistically rational fit. TAZPOWER, a small Phase 2/3 randomized, double-blind, placebo-controlled crossover trial, tested elamipretide against placebo in genetically confirmed patients. Like MMPOWER-3, the blinded crossover portion did not meet its primary endpoints over the short randomized window.^[4] But its open-label extension told a more encouraging story: over roughly 168 weeks of continued treatment, patients showed sustained improvements in functional measures such as exercise capacity and muscle strength, along with measures of cardiac function, with acceptable long-term tolerability.^[5] In an ultra-rare disease with no other treatment and only a few dozen identified US patients, that long-term natural-history-anchored evidence carried unusual weight.

On that basis, the FDA granted accelerated approval to elamipretide — brand name FORZINITY — in September 2025, to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. It is the first FDA-approved mitochondria-targeted therapy.^[6] The two qualifiers matter enormously. First, this is an accelerated approval, granted on the strength of a small dataset in an ultra-rare population, and it carries a requirement for a confirmatory trial to verify clinical benefit.^[6] Second, the approval is specific to Barth syndrome — it says nothing about efficacy in any other condition, and certainly nothing about broad mitochondrial or anti-aging use.

Dry AMD, geographic atrophy, and heart failure: still early, still unproven

Because retinal and cardiac cells are among the most mitochondria-dependent in the body, SS-31 has been probed in dry age-related macular degeneration and in heart failure. In the eye, the small Phase 1 ReCLAIM program in dry AMD with noncentral geographic atrophy reported that daily subcutaneous elamipretide was generally well tolerated with some signals on visual function, but these were early-phase, largely open-label, uncontrolled findings — proof of tolerability and hypothesis, not proof of efficacy.^[7] In heart failure with reduced ejection fraction, a randomized placebo-controlled study of a single infusion did not produce a meaningful change in left-ventricular volumes.^[8] Neither area has delivered a positive, adequately powered efficacy trial. They remain investigational.

The honest bottom line — and the anti-aging question

SS-31 is a rare case where the mechanism is arguably ahead of the evidence rather than behind it. The cardiolipin story is well characterized and genuinely attractive, and it has now yielded one narrow approval in an ultra-rare mitochondrial disease. But the pattern across its human record is consistent: strong rationale, and clinical endpoints that have mostly not been met, with the Barth syndrome win resting on a small accelerated-approval dataset that still needs confirmation. There is no evidence that SS-31 slows aging, improves performance, or benefits otherwise healthy people — the trials were in serious disease, and even there the results were largely disappointing. Anyone hoping mitochondrial repair will translate into a longevity benefit should note how much rigor even a genuinely promising longevity intervention demands; the PEARL rapamycin trial is a useful benchmark for what an honest healthy-population study looks like, and how cautious its conclusions have to be. Practically, elamipretide is available only through its narrow Barth-syndrome approval; anything sold as SS-31 outside that is unapproved and investigational, with no established dosing or safety profile in healthy users. The mechanism is real. The broad human payoff, so far, is not.